Young synovial mesenchymal stem cell-derived exosomes restore chondrocyte mitophagy and alleviate osteoarthritis by delivering miR-10a-5p to target CRTAC1
Year: 2026
Type: article
Abstract: Osteoarthritis (OA) is a chronic whole-joint degenerative disease. Synovial mesenchymal stem cells (SMSCs) and their derived exosomes (SMSC-Exos) have attracted increasing attention because of their close interaction with the joint microenvironment and their paracrine regenerative potential. However, whether donor aging compromises the cartilage-reparative capacity of SMSC-Exos and the key molecular mechanisms underlying this effect remain unclear. Human SMSCs from young and aged donors were isolated and cultured by enzymatic digestion and plastic-adherence selection, and SMSC-Exos were obtained by ultracentrifugation. Exosomes were characterized by transmission electron microscopy, nanoparticle tracking analysis (NTA), exosomal marker detection, and uptake assays. Using an IL-1β-induced human chondrocyte injury model and a destabilization of the medial meniscus (DMM)-induced male mouse OA model, we systematically evaluated the effects of young- and aged-donor SMSC-Exos and intra-articularly delivered synovial cell-targeted AAV-miR-10a-5p on chondrocyte proliferation, migration, apoptosis, oxidative stress, mitochondrial function, matrix metabolism, and OA progression. Exosomal miRNA sequencing, qRT-PCR, dual-luciferase reporter assays, CRTAC1 overexpression rescue experiments, and mitophagy assays were integrated to explore the mechanism of the miR-10a-5p/CRTAC1 axis. Aged donor-derived SMSCs exhibited senescence-associated alterations, including increased cell size, a higher proportion of SA-β-gal-positive cells, and elevated P16, P21, and P53 expression, but retained MSC surface markers and multilineage differentiation capacity. SMSC-Exos from both young and aged donors displayed typical vesicular morphology and were internalized by chondrocytes; however, Young-Exos were superior to Aged-Exos in promoting chondrocyte proliferation and migration, reducing IL-1β-induced apoptosis and ROS accumulation, and restoring mitochondrial membrane potential and mitochondrial network integrity. In vivo, Young-Exos more effectively improved gait abnormalities, pain-related behavior, osteophyte formation, cartilage proteoglycan loss, and COL2A1/MMP-13 imbalance in OA mice than Aged-Exos. miRNA sequencing identified miR-10a-5p as a Young-Exos-enriched candidate associated with autophagy, mitochondrial function, and inflammatory pathways. Mechanistically, miR-10a-5p suppressed CRTAC1 by binding to the human CRTAC1 3′UTR reporter and reduced CRTAC1 expression in chondrocytes. miR-10a-5p increased Parkin and LC3B expression, decreased p62 accumulation, promoted mitochondria-lysosome colocalization, restored COL II and ACAN expression, and inhibited MMP13, whereas CRTAC1 overexpression partially reversed these protective effects. Synovium-targeted intra-articular delivery of AAV-miR-10a-5p reduced CRTAC1 and NLRP3 levels, restored LC3B-associated mitophagy signaling, decreased p62 accumulation, and attenuated DMM-induced cartilage degeneration and synovitis. Donor aging weakens the cartilage-repair potential of SMSC-Exos by reshaping their miRNA cargo. miR-10a-5p enriched in Young-Exos targets CRTAC1, thereby relieving CRTAC1-associated mitochondrial dysfunction and impaired mitophagy, restoring chondrocyte matrix homeostasis, and delaying OA progression. These findings provide a new rationale for donor selection and miRNA engineering in SMSC-Exos–based cell-free therapy for OA.
Source: Journal of Nanobiotechnology
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7233822793
